You are here

ICER

AbbVie's elagolix could put pressure on budgets, ICER estimates

AbbVie's elagolix could put pressure on budgets, ICER estimates

Biopharma Dive

Flag link:

Roche gets double dose of good Hemlibra news with FDA breakthrough, ICER backing

Roche gets double dose of good Hemlibra news with FDA breakthrough, ICER backing

Fierce Pharma

breakthrough status

Flag link:

ICER declares costs of approved CAR-T therapies aligned with clinical benefit

ICER declares costs of approved CAR-T therapies aligned with clinical benefit

BioWorld

Gilead Sciences

Flag link:

Vantage view – Payers OK with CAR-T? Not so fast

Vantage view – Payers OK with CAR-T? Not so fast

EP Vantage

Flag link:

Should pharma fear ICER?

Should pharma fear ICER?

Medical Marketing and Media

Flag link:

New anti-PD1 drugs overpriced, ICER says

New anti-PD1 drugs overpriced, ICER says

BioPharma Dive

Bristol-Myers Squibb

Flag link:

Nonprofit seeks to dispel ‘myths’ about how it assesses drug values

Nonprofit seeks to dispel ‘myths’ about how it assesses drug values

Stat

Flag link: